Search results
Results from the WOW.Com Content Network
A disintegrin and metalloprotease 17 (ADAM17), also called TACE (tumor necrosis factor-α-converting enzyme), is a 70-kDa enzyme that belongs to the ADAM protein family of disintegrins and metalloproteases, activated by substrate presentation.
Hyper-IgD syndrome (Mevalonate kinase deficiency) CIAS1-related diseases: Muckle–Wells syndrome; Familial cold autoinflammatory syndrome, types 1, 2, 3, and 4; Neonatal onset multisystem inflammatory disease; NLRP1 deficiency; PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum, acne) ADAM17 deficiency; Blau syndrome
Smith–Magenis syndrome (SMS), also known as 17p-microdeletion syndrome, is a microdeletion syndrome characterized by an abnormality in the short (p) arm of chromosome 17. [1] It has features including intellectual disability , facial abnormalities, difficulty sleeping, and numerous behavioral problems such as self-harm.
LPIN2, D18S60. Synonyms: Majeed syndrome. Complement component 2 deficiency: Possibly symptomatic of autoimmune diseases, but not a disease. Congenital heart block: May be related to autoimmune activity in the mother. Contact dermatitis: A hypersensitivity. Cushing's syndrome: No consistent evidence of association with autoimmunity.
ADAMs (short for a disintegrin and metalloproteinase) are a family of single-pass transmembrane and secreted metalloendopeptidases. [1] [2] All ADAMs are characterized by a particular domain organization featuring a pro-domain, a metalloprotease, a disintegrin, a cysteine-rich, an epidermal-growth factor like and a transmembrane domain, as well as a C-terminal cytoplasmic tail. [3]
The revised five-factor score is associated with five-year mortality from GPA and is based on these criteria: Age greater than 65 years, cardiac symptoms, gastrointestinal involvement, chronic kidney disease, and the absence of ear, nose, and throat symptoms. [7] With corticosteroids and cyclophosphamide, five-year survival is over 80%. [13]
Symptoms include overactive bladder, decreased stream of urine, hesitancy urinating, and incomplete emptying of the bladder. [19] [20] By age 40, 10% of men will have signs of BPH and by age 60, this percentage increases by 5 fold. Men over the age of 80 have over a 90% chance of developing BPH and almost 80% of men will develop BPH in their ...
Adult-onset immunodeficiency syndrome is a type of immunodeficiency. It is linked to vulnerability to disseminated infections brought on by opportunistic pathogens. People with this condition have increased levels of anti-interferon-gamma autoantibodies. These particular immune system proteins mistakenly target an individual's own tissues.